Overview

CAR-T for r/r Malignant Tumors in Children

Status:
Recruiting

Trial end date:
2021-09-26

Target enrollment:

Participant gender:

Summary

This study is a clinical study of CAR-T treatment of patients with relapsed/refractory malignant tumors in children. The purpose is to evaluate the safety and effectiveness of chimeric antigen receptor T cells in the treatment of relapsed/refractory malignant tumors in children.

Phase:

Early Phase 1

Details

Lead Sponsor:

PersonGen BioTherapeutics (Suzhou) Co., Ltd.